this could lead to patient mismanagement. caring for people with alzheimer’s disease is much different from patients suffering from dlb. patients with dlb are sensitive to certain types of medications that should be avoided as they lead to faster deterioration and death.
“our findings may have a significant impact both for patients and caregivers,” adds francisco oliveira. “in addition, the selection of patients for clinical trials can now be done with more accurate biomarkers.”
dlb is a distressing neurodegenerative brain disease with symptoms common to both alzheimer’s and parkinson’s, but also can entail mood and cognitive swings, sleep disorders and vivid, sometimes terrifying hallucinations.
“it is the second most frequent cause of degenerative dementia in elderly people (15 to 25% of cases at autopsy),” the researchers wrote.
the study is the culmination of almost 20 years of data. “the imaging data was acquired around 1996-1999,” explains dr. oliveira, “these patients were followed from the time of their initial clinical diagnosis (including image collection) to that of their death – in some cases, for about 20 years.”
part of the same team had already published preliminary results in 2002 in the same journal that has now released the new quantitative results. “we did not have all the data then,” said dr. durval costa, the lead author of the study. “now we do.”